News Focus
News Focus
Post# of 257484
Next 10
Followers 843
Posts 122926
Boards Moderated 9
Alias Born 09/05/2002

Re: DewDiligence post# 222088

Tuesday, 02/19/2019 4:39:11 PM

Tuesday, February 19, 2019 4:39:11 PM

Post# of 257484
Keytruda monotherapy in 2L-HCC misses primary endpoints in KEYNOTE-240 study with HR-0.78 for both PFS and OS:

https://www.businesswire.com/news/home/20190219005993/en/Merck-Update-KEYNOTE-240-Phase-3-Study-KEYTRUDA

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today